FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of ...
One of the biggest Medicare Advantage fraud cases has hit a snag, with government officials saying they don’t have access to ...
A preclinical next-gen obesity drug is stacking five mechanisms (in mice). Also, the NIH funding climate is rougher than ever ...
FDA's plan to use AI to speed up trials, Hinge's new migraine device, and boosting cancer screening with texts.
ACA membership is tumbling after Congress failed to extend extra subsidies that helped people afford the coverage.
AstraZeneca will resume expansion of its U.K. R&D operations after the trade deal with the U.S. included measures to lift U.K ...
New FDA contamination testing results on 312 samples from 16 brands confirm the safety of infant formula in the U.S., the ...
The likelihood of snagging NIH grants has plunged to historic lows, forcing academic researchers to resort to a variety of ...
A new tool, OBSCORE, is meant to better define who's at risk for obesity complications, going beyond BMI to include family ...
The runup to next month’s annual meeting of the American Society of Clinical Oncology has started, and a good bit of the Wall ...
Michael Burgess and Larry Bucshon, former Republican congressmen and doctors, weigh in on RFK Jr.’s recent congressional ...
A new social media narrative claims international grads are stealing American doctors’ jobs. These authors did the math to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results